8-K: Vicarious Surgical Announces 1-for-30 Reverse Stock Split to Meet NYSE Listing Requirements

Vicarious Surgical will implement a 1-for-30 reverse stock split to increase its share price and comply with New York Stock Exchange listing rules.

Summary

• Vicarious Surgical has announced a 1-for-30 reverse stock split of its Class A and Class B common stock.
• The reverse stock split was approved by shareholders at the annual meeting on June 10, 2024.
• The primary goal of the split is to increase the per-share trading price and meet the New York Stock Exchange's minimum share price requirement.
• The reverse stock split will be effective as of 4:15 p.m. on June 12, 2024, with trading on a post-split basis commencing on June 13, 2024.
• The number of outstanding Class A shares will decrease from approximately 156,762,690 to 5,225,423, and Class B shares will decrease from approximately 19,619,760 to 653,992.
• The total authorized number of shares will remain unchanged.
• No fractional shares will be issued; instead, shareholders will receive cash for any fractional shares.
• Outstanding options, warrants, and similar securities will be adjusted accordingly.
• The exercise price of warrants will increase to $345.00 per share, and the number of shares they can be exercised for will decrease to approximately 921,620.
• The reverse stock split will not alter any stockholder's percentage ownership, except for adjustments due to fractional shares.

Sentiment

Score: 3

Explanation: The announcement of a reverse stock split is generally viewed negatively by investors as it indicates a struggling share price and potential financial difficulties. While the company states the split is to meet listing requirements, it is not a positive sign.

Positives

• The reverse stock split is intended to bring the company into compliance with the New York Stock Exchange's minimum share price requirement.
• The reverse stock split will not alter any stockholder's percentage ownership, except for adjustments due to fractional shares.

Negatives

• The reverse stock split is a measure to avoid delisting, which is generally not a positive sign for a company's performance.
• The reduction in the number of outstanding shares may make the stock more volatile.

Risks

• The company's ability to raise financing in the future is uncertain.
• The success, cost, and timing of product development activities are subject to risks.
• The company's ability to obtain and maintain regulatory approval for its products is not guaranteed.
• The company faces competition from other companies in the surgical robotics market.
• Economic downturns and market conditions could adversely affect the company's business.

Future Outlook

The company intends to regain compliance with the New York Stock Exchange's listing requirement regarding minimum share price. The company's actual results may differ from its expectations, estimates, and projections.

Management Comments

• The reverse split is primarily intended to increase the Company's per share trading price and bring the Company into compliance with the New York Stock Exchange's listing requirement regarding minimum share price.

Industry Context

Reverse stock splits are often used by companies to avoid delisting from major exchanges when their share price falls below the minimum threshold. This action is not unique to Vicarious Surgical and is a common strategy in the market.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing delisting from major exchanges, such as the NYSE, due to low share prices.
• Other companies in the medical device and robotics sector, such as Intuitive Surgical and Stryker, have not recently undergone reverse stock splits, indicating they are not facing similar share price pressures.
• The 1-for-30 ratio is a relatively large reverse split, suggesting a significant decline in Vicarious Surgical's share price prior to this action.
• Companies like Ocugen and Cassava Sciences have also recently implemented reverse stock splits to maintain their listing status, showing this is a common strategy in the biotech and pharmaceutical sectors.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same, except for adjustments due to fractional shares.
• The reverse stock split may increase the volatility of the stock price.
• The company aims to maintain its listing on the NYSE, which is important for investor confidence.

Next Steps

• The reverse stock split will be effective on June 12, 2024.
• Trading on a post-split basis will begin on June 13, 2024.

Key Dates

Keywords

reverse stock split, NYSE listing, share price, surgical robotics, common stock, warrants, RBOT